THE FUTURE OF PHARMA: EVOLUTIONARY THREATS AND OPPORTUNITIES
Book ID/图书代码： 00870011B51376
English Summary/英文概要： By any standard, the pharmaceutical industry’s historyhas been a successful one. In addition to its profits andshareholder dividends, it has beenseen by investors as relatively low risk and, largely, counter-cyclical to stockmarket trends. However, that important contribution appearsto be petering out, with significant global implications for employees, shareholders, governments and patients. This is not just caused by the economic crisis.
Long before this, several distinct but related streams of evidence emerged that now point to the stalling of the pharmaceutical industry. The Future of Pharma examines the causes of the industry’s potential decline and offers a convincing and rigorous analysis of the options open to it.
What emerges is a landscape defined, on the one hand, by the changing marketplace of mass-market consumers, institutional healthcare systems and wealthy individuals; and on the other by the alternate sources of commercial value - innovative therapies; super-efficient processes, supply chains and operations; and closer customer relations and increasingly tailored health services.
The challenges to the pharmaceutical industry now and in the medium and long-term are very significant. Brian Smith’s highly readable research findings are a wake-up call and a first step forward for anyone concerned with the future of the industry;
whether executive, customer, policymaker or investor.
Chinese Summary/中文概要： 无论以什么标准来说，医药行业无疑曾经是成功的。除了其利润和股息，被投资者相中还以为它风险相对较低，在很大程度上，与股市趋势反周期运转。 然而，这些重要因素开始衰退，这对员工，股东，政府和病人具有重大的全球影响。这不光是经济危机引起的。
很久以前，有几个不同但相关证据开始涌现，现在矛头直指医药行业。《制药业的未来》这本书分析了该行业衰退的潜在原因。令人信服和严密的揭秘了制药业。
情况变了，一方面，大众市场消费者的市场变化，机构的医疗保健系统和富人；另一个方面，其他具有商业价值的替代品——创新疗法；超高效的流程，供应链与运作；更密切的客户关系和更多量身定做的健康服务。
当下、中期和长期的对制药业的挑战，都是非常重要的。布瑞恩•斯密具有高度可读性的研究结果是一个警钟，是关注该行业未来的第一步；无论你是管理者，客户，决策者或是投资者。(兼职翻译-LNL)
Awards/获奖情况：“……这本新书讲了一些新的和不同的东西……如果你工作在制药企业或即使你只是感兴趣发生了什么，都值得一读。”——摘自Amazon.co.uk
About the Author/作者介绍： 布瑞恩•斯密教授在一家医药研发实验室以一个化学研究员开始他的职业生涯，成为一个学者、作者和顾问之前，在技术和营销领域做了20年。 他在OUBS和SDA Bocconi，这两家欧洲领先的商学院工作，他的研究集中在药品和医疗技术市场的战略制定和实施。
布瑞恩还建立了一个专家咨询公司，给世界上该行业诸多大公司提供建议。
Professor Brian D. Smith began his career as a research chemist in a pharmaceutical R&D lab and then spent 20 years in technical and marketing roles before becoming an academic, author and adviser.
Working at OUBS and SDA Bocconi, two of Europe’s leading business schools, his research focuses on strategy creation and implementation in pharmaceutical and medical technology markets.
Brian also runs a specialist consultancy that advises many of the world’s largest companies in this sector.
Format:HARDCOVER
Rights Status/版权销售情况：Simplified Chinese/简体中文：AVAILABLE
Complex/Traditional Chinese/繁体中文：AVAILABLE
Sales in other countries/其他国家销售情况：
原文第一章内容：暂无
手稿：暂无
大纲：暂无